Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841956 · ClinicalTrials.gov registry record · NA
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
A NA study, sponsored by University of California, Davis.
- Terminated
- Registry status
- NA
- Development phase
- 427
- Enrollment target
NCT02841956: Clinical Trial NA study, sponsored by University of California, Davis.
NCT02841956 is a NA study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 427 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02841956, a NA study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- NA
- Development phase
- 427 participants
- Enrollment target
Study Summary
Reducing Duration of Untreated Psychosis (DUP) is a primary goal for improving long-term outcomes in young people with a first episode of psychosis (FEP). The "standard of FEP care" within the US focuses on targeted provider education regarding signs and symptoms of early psychosis to motivate patient referrals to FEP services, followed by initiation of services within largely clinic-based settings Experience at the Early Diagnosis and Preventive Treatment (EDAPT) FEP specialty program at U.C. Davis in Sacramento has identified two important bottlenecks to reducing DUP, consistent with reports in the literature from other FEP clinics. These are 1) delays in the identification of psychotic symptoms by referral sources, and 2) delays or disruptions of patient engagement in specialty FEP care. Building upon a comprehensive and established referral network of 20 sites across the Sacramento area (schools/universities, ER/inpatient hospitals, outpatient mental health, primary care), the investigators will address delays in patient identification and engagement using a two-phase, cluster randomized design. The investigators will consecutively test the impact of two interventions to reduce DUP, defined in this RFA as time from first onset of psychotic symptoms to engagement in FEP specialty care. To address identification delays, the investigators will examine the use of standard targeted provider education plus novel technology-enhanced screening compared to standard targeted provider education alone, testing the hypothesis that the education plus technology-enhanced screening will identify more patients, earlier in their illness. To address engagement delays, the investigators will compare the use of a mobile community-based, telepsychiatry-enhanced engagement team to standard clinic-based procedures for intake, engagement and initiation of treatment, to test the hypothesis that the mobile approach facilitates earlier and more stable engagement, thereby reducing DUP. The
Interventions
- OTHER Electronic Screen + Education (Phase 1)
- OTHER Targeted Provider Education (Phase 1)
- OTHER Community Mobile Engagement (Phase 2)
- OTHER Clinic based Engagement (Phase 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2014-09 |
| Est. Completion | 2020-03-13 |
| Phase | NA |
Why NCT02841956 stopped before completion
NCT02841956 is an interventional study that assigns participants to a tested intervention. The registered 427 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which Electronic Screen + Education (Phase 1) is the first listed.
NCT02841956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02841956 about?
NCT02841956 is a clinical study titled "Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement". Reducing Duration of Untreated Psychosis (DUP) is a primary goal for improving long-term outcomes in young people with a first episode of psychosis (FEP). The "standard of FEP care" within the US focuses on targeted provider education regarding signs and symptoms of early psychosis to motivate patie...
What is the current status of trial NCT02841956?
This trial is currently terminated. It is a NA study. The enrollment target is 427 participants. The study started on 2014-09. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT02841956?
The interventions under investigation include: Electronic Screen + Education (Phase 1) (OTHER), Targeted Provider Education (Phase 1) (OTHER), Community Mobile Engagement (Phase 2) (OTHER), Clinic based Engagement (Phase 2) (OTHER).
Who is sponsoring clinical trial NCT02841956?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02841956's enrollment target sits among peer trials
427 236th of 2000 higher than 1,765 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia